SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris presented positive Phase 3 RAPIDe-3 and long-term CHAPTER-1…

Pharvaris N.V. · PRESS-RELEASE filed Mar 2, 2026 at 06:50 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 2, 2026 at 06:50 ET

Pharvaris presented positive Phase 3 RAPIDe-3 and long-term CHAPTER-1 trial data for deucrictibant, an oral B2 receptor antagonist for treating and preventing hereditary angioedema (HAE) attacks. The drug demonstrated rapid symptom relief (1.28 hours), complete resolution in 11.95 hours, and sustained efficacy with once-daily dosing, supporting its potential as a best-in-class oral therapy. No safety signals were observed over nearly three years of use.

  • RAPIDe-3 Phase 3 trial met primary and all 11 secondary endpoints for on-demand treatment of HAE attacks with deucrictibant.
  • Median time to symptom relief: 1.28 hours (vs. >12 hours placebo); complete resolution in 11.95 hours (vs. >48 hours placebo).
  • CHAPTER-1 open-label extension showed sustained efficacy over ~3 years: attack rate dropped from 2.18 to 0.12 attacks/month; ~50% of patients attack-free.
  • Deucrictibant was well tolerated with no treatment-related serious adverse events or discontinuations.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access